Diabetes Drug Recalled

Missing labels have prompted Mylan Pharmaceuticals Inc to recall nearly 90,000 vials of insulin glargine (insulin glargine-yfgn) injection, according to the May 4, 2022, US Food and Drug Administration (FDA) Enforcement Report.

The recall affects insulin glargine, 100 units/mL, packaged in a 10-mL multiple-dose vial inside a carton (NDC 49502-393-80), from lot BF21002800 (Exp. 8/23). The product was manufactured by Mylan Pharmaceuticals, Morgantown, WV, for Mylan Specialty, Morgantown, WV, and distributed throughout the United States.

Mylan Pharmaceuticals voluntarily initiated the recall April 12, 2022. The FDA has not yet issued a recall classification.

Insulin glargine is a prescription medication indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.